Table 4.

Survival of patients by risk groups

Characteristics	N (%)	OS, median, years (95% CI)	P	PFS, median, years (95% CI)	P	Missing, N (%)
Cytogenetic risk			0.039		0.429	118 (58)
Standard	56 (27)	NR		2.0 (1.0–2.9)
Higha	31 (15)	2.9 (1.1–4.6)		1.2 (0.7–1.8)
ISS stage			0.002		0.044	30 (14)
I	71 (35)	16.1 (7.0–25.3)		2.4 (1.4–3.4)
II	69 (34)	6.4 (3.5–9.2)		1.8 (0.8–2.7)
III	35 (17)	2.5 (0.9–4.0)		0.8 (0.0–1.7)
R-ISS stage			0.008		0.006	123 (60)
I	13 (6)	NR		2.5 (0.0–5.8)
II	55 (27)	8.0 (1.4–14.7)		1.7 (1.0–2.5)
III	14 (7)	1.7 (0.7–2.7)		0.4 (0.1–0.9)
IMWG risk			0.048		0.047	119 (58)
Low	29 (14)	NR		2.0 (0.1–3.8)
Standard	35 (17)	NR		2.5 (1.5–3.4)
High	22 (11)	2.6 (1.1–4.1)		0.6 (0.2–1.0)

^a15 patients (7%) had del17p, 22 (11%) t(4;14), and two (1%) t(14;16)

OS overall survival, PFS progression-free survival, ISS International Staging System, R-ISS Revised International Staging System, IMWG risk International Myeloma Working Group Risk Stratification, NR not reached